Marcelo G Mandile1, Laura E Esteban2, Marcelo H Argüelles2, Alicia Mistchenko3, Graciela Glikmann2, Alejandro A Castello2. 1. Laboratorio de Inmunología y Virología, Universidad Nacional de Quilmes, Roque Sáenz Peña 352, Bernal 1876, Argentina. Electronic address: mgmandile@gmail.com. 2. Laboratorio de Inmunología y Virología, Universidad Nacional de Quilmes, Roque Sáenz Peña 352, Bernal 1876, Argentina. 3. Laboratorio de Virología, Hospital de Niños Ricardo Gutiérrez, Sánchez de Bustamante 1330, Buenos Aires 1425, Argentina.
Abstract
BACKGROUND: Group A rotaviruses (RVA) are the most frequent single etiological agents of severe diarrhea in infants. Since 2006 RVA vaccines have been introduced in national schedules of middle and high income countries with substantial declines in rotavirus associated disease burden. However, surveillance must be maintained to, eventually, detect emerging types or variants selected by the new pressure imposed by vaccination. OBJECTIVES: To analyze the molecular epidemiology of group A rotavirus after vaccine introduction in the region in the context of data from more than 15 years of continuous surveillance in Buenos Aires. STUDY DESIGN: RVA positive diarrhea samples collected in Buenos Aires from 2008 to 2011 were genotyped by RT-PCR. Selected samples were sequenced to gain insight on evolution of common and globally emerging human RVA strains. RESULTS: Lineage III G12P[8] strain emerged in 2008 in Buenos Aires and shared co-dominancy with G3 strains during 2009. An atypical long lasting circulation of G2P[4] strains since 2004 reached rates around 80% in 2011 in Buenos Aires. Sequencing of the VP7 and VP4 genes of representative G2P[4] isolates suggests Brazil as the origin of the 2010-2011 strains. CONCLUSIONS: Globally emergent G12 lineage III strains could be established as dominant strains in a very populated area in two years since emergence. In this work it was also shown that the persistence of G2P[4] strains during 8 years could be related to massive immunization with the monovalent vaccine in the region.
BACKGROUND:Group A rotaviruses (RVA) are the most frequent single etiological agents of severe diarrhea in infants. Since 2006 RVA vaccines have been introduced in national schedules of middle and high income countries with substantial declines in rotavirus associated disease burden. However, surveillance must be maintained to, eventually, detect emerging types or variants selected by the new pressure imposed by vaccination. OBJECTIVES: To analyze the molecular epidemiology of group A rotavirus after vaccine introduction in the region in the context of data from more than 15 years of continuous surveillance in Buenos Aires. STUDY DESIGN: RVA positive diarrhea samples collected in Buenos Aires from 2008 to 2011 were genotyped by RT-PCR. Selected samples were sequenced to gain insight on evolution of common and globally emerging human RVA strains. RESULTS: Lineage III G12P[8] strain emerged in 2008 in Buenos Aires and shared co-dominancy with G3 strains during 2009. An atypical long lasting circulation of G2P[4] strains since 2004 reached rates around 80% in 2011 in Buenos Aires. Sequencing of the VP7 and VP4 genes of representative G2P[4] isolates suggests Brazil as the origin of the 2010-2011 strains. CONCLUSIONS: Globally emergent G12 lineage III strains could be established as dominant strains in a very populated area in two years since emergence. In this work it was also shown that the persistence of G2P[4] strains during 8 years could be related to massive immunization with the monovalent vaccine in the region.
Authors: N A Page; L M Seheri; M J Groome; J Moyes; S Walaza; J Mphahlele; K Kahn; C N Kapongo; H J Zar; S Tempia; C Cohen; S A Madhi Journal: Vaccine Date: 2017-10-27 Impact factor: 3.641
Authors: C Facundo Temprana; Marcelo H Argüelles; Nicolás M Gutierrez; Patricia A Barril; Laura E Esteban; Dalila Silvestre; Marcelo G Mandile; Graciela Glikmann; Alejandro A Castello Journal: PLoS One Date: 2018-09-07 Impact factor: 3.240
Authors: Slavica Mijatovic-Rustempasic; Jose Jaimes; Charity Perkins; M Leanne Ward; Mathew D Esona; Rashi Gautam; Jamie Lewis; Michele Sturgeon; Junaid Panjwani; Gail A Bloom; Steve Miller; Erik Reisdorf; Ann Marie Riley; Morgan A Pence; James Dunn; Rangaraj Selvarangan; Robert C Jerris; Dona DeGroat; Umesh D Parashar; Margaret M Cortese; Michael D Bowen Journal: Viruses Date: 2022-08-15 Impact factor: 5.818
Authors: Casey L McAtee; Rachel Webman; Robert H Gilman; Carolina Mejia; Caryn Bern; Sonia Apaza; Susan Espetia; Mónica Pajuelo; Mayuko Saito; Roxanna Challappa; Richard Soria; Jose P Ribera; Daniel Lozano; Faustino Torrico Journal: Am J Trop Med Hyg Date: 2015-11-23 Impact factor: 2.345
Authors: G M Giammanco; F Bonura; F DI Bernardo; A Cascio; G Ferrera; P Dones; L Saporito; A Collura; D M Terranova; M Valenzise; M T Allù; N Casuccio; M Palermo; K Bányai; V Martella; S DE Grazia Journal: Epidemiol Infect Date: 2016-01-08 Impact factor: 4.434
Authors: Filipe A Carvalho-Costa; Rosane M S de Assis; Alexandre M Fialho; Irene T Araújo; Marcelle F Silva; Mariela M Gómez; Juliana S Andrade; Tatiana L Rose; Tulio M Fumian; Eduardo M Volotão; Marize P Miagostovich; José Paulo G Leite Journal: BMC Pediatr Date: 2019-01-31 Impact factor: 2.125